NCT03158038 - Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2017-2018 Season | Biotech Hunter

Enrollment

300

Participants

Timeline

Start Date

May 30, 2017

Primary Completion Date

December 14, 2017

Study Completion Date

December 14, 2017

Conditions

InfluenzaHealthy

Interventions

BIOLOGICAL

Monovalent Influenza Vaccine

A single dose of monovalent influenza vaccine \[10\^7.0 +/- 0.5 FFU of each of 1 ca, att, ts 6:2 reassortant influenza strain\] will be administered as intranasal spray on Day 1.

OTHER

Placebo

A single dose of placebo matching with monovalent influenza vaccine will be administered as intranasal spray on Day 1.

Trial Locations (2)

30281

Research Site, Stockbridge

97239

Research Site, Portland